Han Biomedical

Han Biomedical Net Debt

The Net Debt of Han Biomedical (6999.TWO) as of Nov 2, 2026 is -200.34 M TWD. In the previous year, Net Debt was -154.18 M TWD — a change of 29.94% (lower).

Net Debt

-200.34 MTWD

YoY

29.94%

Last updated:

Net Debt of Han Biomedical is 2024 -200.34 M TWD. Net Debt of Han Biomedical was 2023 -154.18 M TWD. It decreases by 29.94% lower compared to the previous year.

The Han Biomedical Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2022
-122.70 M TWD
Jan 1, 2023
-154.18 M TWD
Jan 1, 2024
-200.34 M TWD
The Han Biomedical Net Debt history
YEARNet DebtYoY
-200.34 MTWD+29.94%
-154.18 MTWD+25.66%
-122.70 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Han Biomedical Stock analysis

What does Han Biomedical do? Han Biomedical Inc generates revenue through the design, development, and production of medical materials for tissue reconstruction and repair. Its primary products are BarriGel, a post-surgical anti-adhesion solution that prevents complications by extending degradation time, and Hancare, a collagen scaffolding material made from medical-grade collagen that adheres to wounds and absorbs exudate. The company distributes these products mainly within Taiwan's domestic market, targeting healthcare providers and medical facilities that require advanced tissue repair solutions. The firm focuses on natural biomedical materials, emphasizing product innovation for post-surgical care. BarriGel and Hancare are positioned as specialized medical solutions for wound management and adhesion prevention, catering to hospitals and clinics seeking effective tissue repair technologies. Revenue streams are derived from direct sales of these branded products to domestic healthcare institutions without external distribution channels. Han Biomedical Inc's business model centers on proprietary medical materials developed for specific clinical applications. The company's product portfolio includes BarriGel and Hancare, both designed to address post-surgical challenges with natural materials. Domestic market distribution ensures consistent revenue from local healthcare providers who prioritize advanced tissue repair solutions. Han Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Han Biomedical stock

Net Debt of Han Biomedical is -200.34 M TWD in 2024.

Net Debt of Han Biomedical changed from -154.18 M TWD to -200.34 M TWD, representing a 29.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Han Biomedical since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Han Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Han Biomedical

All Key Metrics — Han Biomedical